Centinel Spine, a medical device company, has announced that further to its strategic integration plan with Surgicraft Group Holdings, the company has retained exclusive US-distribution rights to the Stalif TT stand alone lumbar interbody fusion device technology with immediate effect.
Subscribe to our email newsletter
As a consequence, Centinel Spine now has exclusive distribution rights to market Stalif TT products in all markets and countries globally. Centinel Spine expects to see increased revenue from this technology as early as first quarter of 2009.
John Viscogliosi, chairman and CEO of Centinel Spine, said: “The addition of the Stalif TT system to our product portfolio continues our winning formula of no profile stand alone interbody fusion technologies. It allows the company to benefit from the strengths of the Stalif TT technology in the form of tried and true proven scientific and clinical outcomes.
“With our improved and rapidly expanding distribution channels the Stalif TT will allow Centinel to significantly increase revenue while benefiting patients throughout the US.”
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.